The Russian parent company produces the vaccine Sputnik V.
(Photo: dpa)
Moscow Although a timely EU approval for the Russian vector vaccine Sputnik V is becoming increasingly unlikely, the Russian pharmaceutical company R-Pharm is insisting on its plans for a Sputnik production in Bavaria. A corresponding laboratory for production in Illertissen in the Neu-Ulm district was only completed a few weeks ago.
According to the company, up to 150 million doses of the Sputnik vaccine and the in-house Covid drug Artlegia should roll off the production line in the factory every year. For this purpose, R-Pharm has already signed a loan agreement with the Raiffeisenbank. The company will receive 50 million euros for the expansion of capacities. The loan runs for three years. But first of all, according to reports, R-Pharm will produce the Astra-Zeneca vaccine Vaxzevria in Illertissen.
Read on now
Get access to this and every other article in the
Web and in our app for 4 weeks free of charge.
Further
Read on now
Get access to this and every other article in the
Web and in our app for 4 weeks free of charge.
Further